Brokerages Set Spero Therapeutics Inc (SPRO) Target Price at $22.33

Spero Therapeutics Inc (NASDAQ:SPRO) has been given an average recommendation of “Hold” by the six research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $22.33.

A number of research firms have recently weighed in on SPRO. ValuEngine cut Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research cut Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 12th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Sunday, January 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Friday, March 15th.

Spero Therapeutics stock traded up $0.28 during midday trading on Wednesday, reaching $14.38. The company’s stock had a trading volume of 97,370 shares, compared to its average volume of 116,146. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $19.00. The company has a market cap of $242.80 million, a P/E ratio of -5.53 and a beta of 2.97.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.15. Spero Therapeutics had a negative net margin of 1,050.48% and a negative return on equity of 43.63%. The business had revenue of $1.69 million for the quarter, compared to analysts’ expectations of $0.84 million. On average, equities analysts anticipate that Spero Therapeutics will post -3.41 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC acquired a new stake in Spero Therapeutics during the 3rd quarter worth approximately $9,383,000. Aquilo Capital Management LLC increased its stake in Spero Therapeutics by 91.9% during the third quarter. Aquilo Capital Management LLC now owns 799,691 shares of the company’s stock valued at $8,405,000 after purchasing an additional 383,000 shares during the last quarter. Vanguard Group Inc grew its position in shares of Spero Therapeutics by 264.8% during the 3rd quarter. Vanguard Group Inc now owns 455,416 shares of the company’s stock valued at $4,787,000 after buying an additional 330,580 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Spero Therapeutics by 264.8% during the third quarter. Vanguard Group Inc. now owns 455,416 shares of the company’s stock valued at $4,787,000 after purchasing an additional 330,580 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Spero Therapeutics by 5.7% during the 4th quarter. BlackRock Inc. now owns 393,630 shares of the company’s stock worth $2,421,000 after buying an additional 21,161 shares during the last quarter. Hedge funds and other institutional investors own 46.32% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Featured Article: What does EPS mean?

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.